Filing Flows › Crispr Therapeutics AG (CRSP) › R&D spending
Crispr Therapeutics AG (CRSP) R&D spending by quarter
Crispr Therapeutics AG's R&D spending was $71.9M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $58.9M (Q3 2025) to $83.5M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $71.9M | +7% | +22% |
| Q2 2026 | $67.2M | -2% | -4% |
| Q1 2026 | $68.6M | -18% | -5% |
| Q4 2025 | $83.5M | +42% | — |
| Q3 2025 | $58.9M | -16% | — |
| Q2 2025 | $69.9M | -4% | — |
| Q1 2025 | $72.5M | — | — |
Q3 2026 at a glance
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Crispr Therapeutics AG's R&D spending?
Crispr Therapeutics AG's R&D spending was $71.9M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Crispr Therapeutics AG's R&D spending changed?
Over the last 7 quarters it ranged from $58.9M (Q3 2025) to $83.5M (Q4 2025).
Q3 2026 results → · How Crispr Therapeutics AG makes money →